Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 14, 2008
Last updated: February 5, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2012
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)